Serina Therapeutics (SER) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Serina Therapeutics (SER) overview

Serina Therapeutics (SER) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.1m and operating profit of USD -24.0m; the year-end share price was 1.91 USD and market capitalisation was USD 20.6m. Serina Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Serina Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -0.0mFY 2025
Share price1.91 USDFY 2025 year end
RevenueUSD 0.1mFY 2025
Operating profitUSD -24.0mFY 2025
Net earningsUSD -19.2mFY 2025
Market capitalisationUSD 20.6mFY 2025 year end

About Serina Therapeutics

Serina Therapeutics is a clinical-stage biotechnology company developing drug candidates using its POZ polymer delivery technology. The platform is designed to modify small molecules and other therapeutic agents for controlled drug loading and release, including through long-acting subcutaneous injection. Its pipeline focuses on neurological diseases, including Parkinson’s disease, and the company is also exploring other therapeutic applications through partnerships.

Generate the Serina Therapeutics report

Serina Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Serina Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Serina Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.